Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0UBXSP)
| ADC Name |
DB-1418
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
DB-1418; AVZO-1418
Click to Show/Hide
|
|||||
| Organization |
Duality Biotherapeutics (DualityBio) (Originator);Avenzo Therapeutics
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-EGFR/HER3 bsAb
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3)
|
Antigen Info | ||||
| Payload Name |
P1021
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
drozuntecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
83%
|
|||
| Method Description |
In the EGFR-dominant CAL-27 model, DB-1418 demonstrated a significant tumor growth inhibition (TGI) of 83% at a dose of 1.9 mg/kg Q3W
|
||||
| In Vivo Model | EGFR-dominant CAL-27 model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
98%
|
|||
| Method Description |
Notably, in an osimertinib-resistant NSCLC xenograft model with the C797S mutation, DB-1418 induced tumor regression with a TGI of 98% at a dose of 6 mg/kg Q3W.
|
||||
| In Vivo Model | Osimertinib-resistant NSCLC xenograft model with the C797S mutation | ||||
References